Ductal carcinoma in situ of the breast in Israeli women treated by breast-conserving surgery followed by radiation therapy.
BACKGROUND
Lumpectomy followed by radiation therapy (RT) has become an accepted local management strategy for patients with small, mammographically detected ductal carcinoma in situ (DCIS) of the breast. The aim of this analysis is to describe control rates and patterns of relapse in a cohort of Israeli women with mammographically detected DCIS treated at a single medical center.


METHODS
The files of 107 consecutive patients with DCIS were retrieved from the cancer registry of the unit of RT. All women underwent lumpectomy followed by definitive RT, administered in conventional dose fractionation regimens. Oral tamoxifen, 20 mg/ day, was prescribed to all but 2 patients with positive receptors.


RESULTS
Within a median follow-up time of 52 months, no local recurrence of any breast tumor was found. There was no correlation between event-free survival and tumor size, focality, grading, hormone receptor status, administration of adjuvant hormonal therapy, timing of RT, and RT boost delivery. The 8-year overall survival, disease-free-survival, and event-free survival were 100, 100, and 87%, respectively.


CONCLUSIONS
The results reported herein are consistent with short-term and intermediate-term outcomes that are better than the reported benchmarks from prospective randomized trials. Although this could reflect selection factors at a single institution, it is also plausible that a genetically distinct disease is present in this local population.
Jiveliouk
Irina
I
Department of Oncology, Tel-Aviv Sourasky Medical Center, affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Corn
Benjamin
B
Inbar
Moshe
M
Merimsky
Ofer
O
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D002278:Carcinoma in Situ / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007557:Israel; D008327:Mammography; D015412:Mastectomy, Segmental / Q000379:methods*; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone